Browse by author
Lookup NU author(s): Dr Lindi Chen, Angharad Humphreys, Dr Lisa Turnbull, Dr Nicholas Bown, Professor Deborah Tweddle
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Anaplastic Lymphoma Kinase (ALK) is a transmembrane receptor kinase that belongs to the insulin receptor superfamily and has previously been shown to play a role in cell proliferation, migration and invasion in neuroblastoma. Activating ALK mutations are reported in both hereditary and sporadic neuroblastoma tumours, and several ALK inhibitors are currently under clinical evaluation as novel treatments for neuroblastoma. Overall, mutations at codons F1174, R1275 and F1245 together account for ~85% of reported ALK mutations in neuroblastoma. NBLW and NBLW-R are paired cell lines originally derived from an infant with metastatic MYCN amplified Stage IVS (Evans Criteria) neuroblastoma, at diagnosis and relapse, respectively. Using both Sanger and targeted deep sequencing, this study describes the identification of distinct ALK mutations in these paired cell lines, including the rare R1275L mutation, which has not previously been reported in a neuroblastoma cell line. Analysis of the sensitivity of NBLW and NBLW-R cells to a panel of ALK inhibitors (TAE-684, Crizotinib, Alectinib and Lorlatinib) revealed differences between the paired cell lines, and overall NBLW-R cells with the F1174L mutation were more resistant to ALK inhibitor induced apoptosis compared with NBLW cells. This pair of cell lines represents a valuable pre-clinical model of clonal evolution of ALK mutations associated with neuroblastoma progression.
Author(s): Chen L, Humphreys A, Turnbull L, Bellini A, Schleiermacher G, Salwen H, Cohn SL, Bown N, Tweddle DA
Publication type: Article
Publication status: Published
Journal: Oncotarget
Year: 2016
Volume: 7
Pages: 87301-87311
Online publication date: 24/11/2016
Acceptance date: 06/11/2016
Date deposited: 05/12/2016
ISSN (electronic): 1949-2553
Publisher: Impact Journal LLC
URL: http://dx.doi.org/10.18632/oncotarget.13541
DOI: 10.18632/oncotarget.13541
PubMed id: 27888620
Altmetrics provided by Altmetric
